摘要
目的：分析阿帕替尼联合替吉奥治疗晚期结直肠癌的临床疗效及安全性。方法：回顾性分析2019年6月至2020年6月我院40例一线及二线化疗失败的晚期结直肠癌患者的临床资料，均采用阿帕替尼联合替吉奥进行三线治疗，总结其治疗效果、患者肿瘤进展时间、总生存时间以及化疗毒副反应发生情况。结果：40例患者中部分缓解18例，无变化或稳定16例，进展6例，临床有效率45.00%，临床受益率85.00%。40例肿瘤进展时间平均(5.18±0.96)个月，总生存时间平均(7.98±2.66)个月。化疗相关毒副反应为乏力(30.0%)、恶心呕吐(27.50%)、骨髓抑制(22.50%)、贫血(15.0%)、高血压(7.50%)、手足综合征(5.0%)、口腔黏膜炎(2.50%)、腹泻(7.50%)、食欲下降(32.50%)，上述均属于1-2级毒副反应，无3-4级毒副反应发生。结论：阿帕替尼联合替吉奥三线治疗晚期结直肠癌效果良好，且患者对不良反应可耐受，可以作为晚期结直肠癌三线治疗的选择。
关键词： 晚期结直肠癌；三线治疗；替吉奥；阿帕替尼；靶向治疗；联合化疗
Abstract
Objective:To analyze the clinical efficacy and safety of alpatinib combined with tegafur in the treatment of advanced colorectal cancer.Methods:The clinical data of 40 cases of patients with advanced colorectal cancer who failed first-line and second-line chemotherapy from June 2019 to June 2020 were retrospectively analyzed.All patients were treated with apatinib combined with tegafur for the third line treatment.The patient's treatment effect,time to tumor progression,overall survival time,and occurrence of side effects of chemotherapy were summarized.Results:Among the 40 patients,18 had partial remission,16 had no change or stability,and 6 had progressed.The clinical effective rate was 45.00%and the clinical benefit rate was 85.00%.The average tumor progression time of 40 patients was(5.18±0.96)months,and the average overall survival time was(7.98±2.66)months.The side effects of chemotherapy were fatigue(30.0%),nausea and vomiting(27.50%),myelosuppression(22.50%),anemia(15.0%),hypertension(7.50%),hand foot syndrome(5.0%),oral mucositis(2.50%),diarrhea(7.50%),and loss of appetite(32.50%).All of the above were grade 1-2 toxicities,and no grade 3-4 side effects occurred.Conclusion :Apatinib combined with tegafur in the third line treatment of advanced colorectal cancer has good effect,and the patients can tolerate adverse reactions,so it can be used as the third line treatment of advanced colorectal cancer.
Key words： Advanced Colorectal Cancer;Tegafur;Apatinib;Targeted Therapy;Combination Chemotherapy
参考文献 References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]